Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of pathophysiological mechanisms and therapeutic targets without original human data or systematic synthesis
PubMed 15184729 · doi:10.1111/j.1527-5299.2004.03223.x
What was done
This narrative review summarizes the nonenzymatic formation of advanced glycation end products (AGEs), their biological cross-linking mechanisms in the cardiovascular system, their role in aging- and diabetes-related cardiovascular disease, and emerging pharmacological strategies designed to prevent, break, or block AGEs.
What was found
The abstract reports no quantitative data, statistics, or numerical effect sizes. It describes qualitative pathophysiologic pathways whereby AGE accumulation leads to collagen cross-linking and receptor-mediated signaling, contributing to increased vascular and myocardial stiffness, endothelial dysfunction, and atherosclerotic plaque formation.
Why it matters
The review outlines how targeting glycation cross-links could provide therapeutic avenues to lower cardiovascular stiffness and reduce the risk of isolated systolic hypertension, diastolic dysfunction, and heart failure.
Limits
As a narrative review, it presents mechanism-based concepts rather than original experimental or clinical trial data. No systematic search methodology, sample sizes, or quantitative outcome metrics are reported in the abstract.
Cited by
- supports Elevated blood glucose reacts with collagen in blood vessels and the myocardium via the Maillard reaction (glycation), leading to tissue cross-linking and vascular/cardiac stiffness.